Progressive multifocal leukoencephalopathy (PML) is a rare and usually untreatable progressive, demyelinating neurologic condition caused by the JC papovavirus. In persons with human immunodeficiency virus (HIV) infection, PML is an AIDSdefining condition, and average survival time after the onset of neurologic conditions has been estimated at 4 months [1] . PML occurs in 2%-4% of patients with AIDS [1, 2] and is recorded as a cause of death for 0.7% of patients with AIDS [3] .
Treatment for PML has included cytarabine (cytosine arabinoside, Ara-C), which has not been successful in patients with AIDS [4, 5] . Zidovudine monotherapy, though it has been associated with clinical improvement [6] , has not commonly been prescribed in recent years, because combination antiretroviral therapy (ART) has been used more successfully in treating HIV infection. A recent study of cytarabine, in which one group received ART alone and another received ART with cytarabine, did not demonstrate a survival benefit for patients with PML who received ART, compared with the survival of patients with PML reported in the medical literature [1, 5] . However, this study was conducted before highly active ART (HAART) (i.e., triple combination therapy that includes a protease inhibitor) became widely prescribed.
Because PML has such a poor prognosis and limited treatment options, the factors associated with survival could be important in developing strategies for treatment and guiding prognostic decisions. To examine survival factors, we analyzed data from the Adult and Adolescent Spectrum of HIV Disease (ASD) surveillance project, a longitudinal, national multicenter surveillance project that collects information on AIDS-defining and other conditions in HIV-infected persons.
Methods
The methods for ASD have been reported elsewhere [7] . ASD is a national surveillance project of the Centers for Disease Control and Prevention (CDC) in collaboration with 11 state and local health departments, in which information is abstracted from the medical records of HIV-infected patients at selected health care facilities. The initial abstraction is a review of the year before patient selection and is followed by 6-month abstractions until death or loss to follow-up. Staff began abstracting at project sites in 1990 (Atlanta, GA; Dallas, Houston, and San Antonio, TX; Denver, CO; Detroit, MI; Los Angeles, CA; New Orleans, LA; Seattle, WA), 1991 (New York, NY), and 1992 (Bayamon, Puerto Rico). Participating facilities include hospitals, outpatient offices, and emergency rooms.
To make ASD similar to national AIDS reports, sampling of patients for inclusion is conducted at some sites: 50% of African American males in Atlanta since January 1994; 25%-50% of white males in Dallas, San Antonio, and selected sites in Seattle since approximately 1990-1991; no white males (except intravenous drug users [IDUs]) for some Los Angeles sites since 1992; 40%-50% of all men at Detroit sites since 1993; and 16%-50% (since January 1995) for white males at some New York sites.
Patients with PML met the CDC AIDS case definition, which requires a histologic or cytologic diagnosis for PML. These patients were observed in ASD from 1990 to 1997 and followed through August 1998. A counting-process formulation of the Cox model was used to determine the factors associated with survival time after PML diagnosis [8] . The assumptions of proportional hazards were validated by use of plots of weighted Schoenfeld residuals versus time [9] . The model included gender, age categories, HIV transmission risk mode, race, and CD4 ϩ T lymphocyte categories. Also included in the model were the presence of seizure, herpes zoster, alcoholism, molluscum contagiosum, whether PML was the first AIDS illness (AIDS-defining), diagnosis of an AIDS-defining illness other than PML, and prescription of antiherpesvirus and antiretroviral medication with or without a protease inhibitor during the interval of observation at or after the diagnosis of PML. Diagnosis of herpes zoster, alcoholism, or seizure was indicated if they occurred before or during the interval of observation (at PML diagnosis or during follow-up). Diagnosis of other AIDS-defining illness was indicated if it occurred during or after the interval of observation. Medications were evaluated as interval-specific. Antiherpesvirus medications were acyclovir, famciclovir, valacyclovir, ganciclovir, foscarnet, and cidofovir. Antiretroviral medications were zidovudine, zalcitabine, didanosine, lamivudine, stavudine, abacavir, adefovir, delavirdine, nevirapine, efavirenz, saquinavir, indinavir, ritonavir, and nelfinavir.
The Kaplan-Meier method was used to estimate survival probabilities [10] . We excluded the persons for whom PML was diagnosed before enrollment. Survival in the number of months after diagnosis of PML was calculated for 354 patients whose PML diagnosis was made at or after their first observation period in ASD. For the 354 patients, the median survival was 1 month. Estimated 6-month survival was only 17%.
Results

PML
Survival time for persons with PML was longest for persons who were prescribed ART that included a protease inhibitor ( figure 1 ). The estimated 6-month survival time after diagnosis of PML for persons who were prescribed ART with a protease inhibitor during or after the interval of PML diagnosis was 68%, compared with 21% for persons who were prescribed ART without a protease inhibitor and 10% for persons for whom ART was not prescribed.
In the multivariate analysis, the prescription of an antiretroviral medication (relative risk [RR], 0.6; 95% confidence interval [CI], 0.5-0.8) without a protease inhibitor compared with no antiretroviral medication was associated with a decreased risk for death (table 1) . When the medication included a protease inhibitor, the risk for death decreased even more (RR, 0.2; CI, 0.1-0.4). We also examined the timing of the prescription, for example, protease inhibitor prescription prior to diagnosis of PML, and found that it was not associated with prolonged survival. However, the occurrence of PML as the AIDSdefining illness was associated with prolonged survival (RR, 0.6; CI, 0.5-0.7).
Factors associated with poor survival were CD4 ϩ T lymphocyte count ! /L at the time of PML diagnosis, 9 0.20 ϫ 10 prior or concurrent diagnosis of seizure disorder, and molluscum contagiosum (table 1) . Gender, age, mode of transmission, race, alcoholism, herpes zoster, diagnosis of another AIDS condition, and the prescription of an antiherpesvirus medication were not significantly associated with survival.
When examining the effect of the CD4 ϩ T lymphocyte response to antiretroviral therapy on survival with PML by adding a variable to the model that represented a CD4 ϩ T lymphocyte increase of у /L cells, patients whose CD4 
Discussion
We found a significant reduction in the risk for death with PML associated with prescription of ART, especially ART that included a protease inhibitor. Recent trends in the AIDS epidemic have demonstrated improving mortality [11] . McNaghten et al. demonstrated recently that improved survival with AIDS is associated with combination ART [12] . However, improved survival with AIDS does not necessarily mean that combination ART is associated with improved survival for each AIDS-defining illness. Our study documents the influence of these medications on the prognosis of PML. This influence is especially remarkable because there has been no generally successful treatment for PML. With the exception of occasional reports of prolonged survival and partial recovery, the progression of disease and death has often followed soon after the diagnosis of PML [13] . A recent study by Berger et al. did not demonstrate an association between treatment modalities and survival, but did find that PML as the AIDS-defining illness, a high CD4 ϩ T lymphocyte cell count at disease onset, lesion enhancement on computed tomographic scan or magnetic resonance imaging, and evidence of recovery of neurologic function were predictors of long-term survival in 7 patients who survived beyond 12 months from symptom onset [14] . Our findings support the influence of PML as the AIDS-defining illness on survival. This influence might be related to early diagnosis in the course of AIDS, perhaps associated with higher CD4 ϩ cell counts.
While there is experimental evidence that PML might result from HIV type 1 nuclear protein Tat's increasing transcriptional activity of the JC viral genome in glial cells [15] , PML is primarily a consequence of immunosuppression. HAART seems to restore at least part of the damaged immune system in patients who respond to this therapy. Recent case reports (including 1 patient who had a splenectomy) have suggested that HAART may lead to regression or remission of PML [16, 17] . The reversal of immunosuppression seems to be a key factor in affecting the prognosis of PML, as suggested by the association with protease inhibitor prescription already mentioned and by a case report of a patient who had a remission of PML after discontinuing immunosuppressive drugs [18] . In our study, a CD4 ϩ T lymphocyte cell count ! /L was also in-9 0.20 ϫ 10 dependently associated with poor survival. We also found that patients whose CD4
ϩ cell counts had been ! /L and 9 0.20 ϫ 10 increased by у /L had a significantly better survival 9 0.10 ϫ 10 outcome than patients with no change, a CD4 ϩ cell decline, or a CD4
ϩ cell count unknown. Recently published information on 10 HIV-infected patients with PML, in whom HAART was initiated within 90 days of the onset of symptoms, demonstrated relatively long-term survival (median 430 days) after diagnosis of PML [19] . For 5 of these patients, JC virus DNA was no longer detectable in cerebrospinal fluid. These findings support the importance of the reversal of immunosuppression in improving the prognosis of PML.
The presence of seizure disorder during the interval of or before the diagnosis of PML was associated with poor survival. Seizures have been reported to occur when PML extends into the cortical gray matter [20] . Seizures may be secondary to HIV, to other debilitating processes such as concurrent infections, or to drug-induced side effects, any of which could contribute to morbidity and mortality.
Overall, the median survival time of patients with PML after diagnosis in our study was only 1 month. This finding is probably shorter than the 2.5-4 months average survival reported elsewhere, because in our study, diagnosis is recorded at confirmation (biopsy or autopsy) rather than at symptom onset [1, 21] . The prevalence of PML among persons with AIDS who died (2.4%) is higher than that reported by Holman et al., who found a prevalence of 0.72% among persons with AIDS reported to CDC from 1981 to June 1990 [3] . Because not all patients in the study by Holman et al. had died and therefore not all their AIDS-related conditions had developed, it is expected that our prevalence might be even higher. Because the ASD population is large and earlier prevalence data came from the previous decade and were derived from vital statistics data that are less complete than data from ASD, we believe that the prevalence of PML presented here is probably the best estimate for persons with AIDS who have died in the United States in this decade.
Limitations of this study include the fact that ASD is not based on population. However, ASD does contain data from a diverse group of HIV-infected patients in the United States and is similar to data from national AIDS reports by race and sex. Also, ASD collects information on the prescription of antiretroviral medications but not on patient adherence, dates on which patients took their medications, or the reasons for prescriptions. However, if adherence to ART was poor, our estimates of the beneficial effects of ART would be conservative. ASD is based on the abstraction of medical records and is therefore limited to information in the medical record at the participating institution. This could lead to an underestimation of other nondemographic variables examined in our study. We cannot rule out the possibility of survivor bias, because it is possible that patients who died soon after diagnosis were less likely to have had the opportunity to be prescribed medication that contained a protease inhibitor. Finally, viral load data have only recently begun to be collected in ASD; sufficient viral load data were not yet available for this analysis.
We recommend that efforts to reverse immunosuppression be used for patients with PML, because the mortality for this disease is high and rapid. Efforts should include HAART (e.g., ART that includes a protease inhibitor and 2 other antiretroviral medications) in conjunction with monitoring of viral load, discontinuation of immunosuppressive medications (such as steroids or certain chemotherapies), exploration of possible adherence issues with patients who are taking potent antiretrovirals but for whom the therapy is failing, and carefully review of the patient's medication list for possible drug interactions with antiretroviral medications that the patient might already be taking. Ideally, patients should be offered HAART before the onset of PML. However, because early HIV testing and access to care are not universally available to all groups at risk for HIV, the importance of early testing and entering care in preventing or delaying AIDS-related conditions cannot be overstressed. Research efforts need to be focused on antiviral medications that are effective against the JC virus because, in some patients, the efforts to reverse immunosuppression will not be sufficient to affect the mortality associated with PML.
